Local Consolidative Therapy Fails to Improve Survival in LONESTAR Trial

Adding local consolidative therapy after induction dual checkpoint blockade in metastatic non-small cell lung cancer was feasible, but it did not improve overall survival or progression-free survival in the phase 3 LONESTAR trial (NCT03391869), according to findings presented by Mehmet Altan, MD, of MD Anderson Cancer Center at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul this week.

Adding local consolidative therapy after induction dual checkpoint blockade was feasible, but it did not improve overall survival or progression-free survival in the overall population or among patients with oligometastatic disease, Altan said in a statement accompanying the data. At a WCLC press briefing, Altan added that the findings do not support routine local consolidation therapy after ipilimumab and nivolumab induction in metastatic non-small cell lung cancer.

LONESTAR Trial Design and Intent

The Phase III LONESTAR trial was an open-label, single-center, randomized study in immunotherapy-naive patients with metastatic non-small cell lung cancer (NSCLC). The trial tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control. After 12 weeks of induction nivolumab (Opdivo) plus ipilimumab (Yervoy), patients without progression or dose-limiting toxicity were randomized to continue nivolumab/ipilimumab alone or receive local consolidative therapy (LCT) followed by nivolumab/ipilimumab. LCT consisted of radiation to at least one disease site, with surgery performed when feasible.

Though added LCT did not incur new safety signals following nivolumab plus ipilimumab nor did it increase grade ≥3 treatment-related adverse events (TRAEs), LONESTAR was closed early for futility after a data safety monitoring board (DSMB) reviewed outcomes of 166 of the planned 216 trial participants.

Local consolidative therapy has been linked to improved outcomes in certain patients with oligometastatic NSCLC treated with chemotherapy. Altan and colleagues described that multiple mid-to-late stage trials—including most recently, NORTHSTAR (NCT04479306) and NRG-LU002 (NCT03137771)—have shown using it to eradicate residual or resistant clones, though its role in patients receiving immune checkpoint inhibitors has remained uncertain.

Survival Outcomes in the Phase III LONESTAR Trial

In the phase III trial, the median overall survival (OS) was 43.2 months with LCT plus nivolumab-ipilimumab versus 52.8 months with nivolumab-ipilimumab alone (HR 1.14, 95% CI 0.75-1.74, P=0.54). There was also a negative OS trend among patients with oligometastatic disease in the LCT-dual immunotherapy arm, with a median OS of 42.0 months compared with 75.8 months in the nivolumab-ipilimumab alone arm (HR 1.68, 95% CI 0.87-3.26, P=0.12).

Local Consolidative Therapy Fails to Improve Survival in LONESTAR Trial — Photo: News-Medical

The strategy also failed to provide statistically significant improvement in progression-free survival (PFS). Among all patients, median PFS was 31.3 months in the LCT-dual immunotherapy arm versus 24.3 months in the nivolumab-ipilimumab alone arm (HR 0.79, 95% CI 0.54-1.15, P=0.22), while among patients with oligometastatic disease, median PFS was 35.7 months and 44.0 months, respectively (HR 1.38, 95% CI 0.76-2.52, P=0.284). Even patients with oligometastatic NSCLC receiving LCT following the immune checkpoint inhibitor regimen did not report improved OS nor PFS through 90 weeks.

Mehmet Altan, MD Anderson Cancer Center

Research presented by Mehmet Altan, M.D., of MD Anderson Cancer Center, Houston, Texas, at the IASLC 2026 World Conference on Lung Cancer in Seoul, outlined that patients with metastatic non-small cell lung cancer did not experience enhanced survival benefits from the addition of local consolidative therapy following dual checkpoint blockade induction.

LCT After Nivolumab/Ipilimumab Induction Fails to Improve Metastatic NSCLC Survival | OncLive — Photo: OncLive

Safety Profile and Lymphocyte Counts Following Radiation

Added local consolidative therapy post-induction with nivolumab plus ipilimumab did not improve overall nor progression-free survival, and while it did not incur new safety signals following nivolumab plus ipilimumab nor increase grade ≥3 treatment-related adverse events, the trial was ultimately closed early for futility.

Clinical Implications and Expert Recommendations

The clinical findings demonstrate that although local consolidative therapy has improved outcomes in selected patients with oligometastatic NSCLC treated with chemotherapy, its application following immune checkpoint inhibitor regimens like nivolumab plus ipilimumab requires careful re-evaluation. Readers can conclude from the phase 3 LONESTAR trial evidence that adding LCT after induction dual checkpoint blockade is feasible but fails to improve overall survival or progression-free survival in the overall population or among patients with oligometastatic disease. Patients considering treatment options should consult qualified healthcare professionals for medical advice tailored to their specific clinical circumstances.